Life Science Washington Institute Named BARDA DRIVe Accelerator

Jul. 9, 2018 | DRIVe

Life Science Washington Institute has been selected as one of eight accelerators in the nation to help drive innovation in lifesaving medical technologies that solve challenging problems spanning modern health security threats and daily medical care.

The U.S. Department of Health and Human Services (HHS) has launched a new initiative to partner with the investment and innovator communities to develop transformative solutions to the toughest health security problems that span the entire health sector. The new approach signals to the investors and innovators that HHS is open for business and that the time is uniquely now to leverage advances in biotech and information technology.

This program was announced in June 2018 by the HHS Assistant Secretary for Preparedness and Response, an agency of HHS devoted to saving lives and protecting Americans from modern health threats which oversees the Biomedical Advanced Research and Development Authority (BARDA). This innovation initiative will be run by the new Division for Research, Innovation, and Ventures – and known as “DRIVe.”

DRIVe offers an attractive, and iterative, opportunity for the investment community to engage with the federal government with a newly streamlined, federal contracting processes designed to mitigate business risk and enable investors to serve the nation. The time is uniquely now to bring health security solutions to the previously unsolvable.

“Life Science Washington Institute is thrilled to have been selected as one of eight inaugural accelerators for the BARDA DRIVe network,” said Dr. Francisco R. Velázquez, Executive Director of Life Science Washington Institute.  “Extraordinary strengths in global health and infectious disease research combined with decades of successfully commercializing breakthrough diagnostics, therapies and medical devices make Washington state the ideal hub for helping to bring innovations in health security to the market faster.”

Read full press release HERE

Comments are closed.